Citi Reaffirms Their Buy Rating on GoodRx Holdings (GDRX)

In a report released today, Daniel Grosslight from Citi maintained a Buy rating on GoodRx Holdings, with a price target of $5.75. The company’s shares closed yesterday at $3.98.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Grosslight is a 3-star analyst with an average return of 3.9% and a 44.91% success rate. Grosslight covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Evolent Health, and Teladoc.

In addition to Citi, GoodRx Holdings also received a Buy from TD Cowen’s Charles Rhyee in a report issued on October 15. However, on the same day, Bank of America Securities maintained a Sell rating on GoodRx Holdings (NASDAQ: GDRX).

Based on GoodRx Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $203.07 million and a net profit of $12.84 million. In comparison, last year the company earned a revenue of $200.61 million and had a net profit of $6.69 million

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GDRX in relation to earlier this year. Earlier this month, Spectrum Equity VII, L.P., a Major Shareholder at GDRX sold 23,771.00 shares for a total of $95,084.00.